Potential approval of a high value complex generic on the same lines as gRevlimid can be a positive surprise, adds the brokerage.

Revenue grew 11.4% to Rs 8,572 crore, but the bottom line of Rs 1,418 crore missed Bloomberg’s consensus estimate of Rs 1,514 crore.